Amgen Highlights The Latest EVENITY (Romosozumab) And Prolia (Denosumab) Research At American Society for Bone and Mineral Research Annual Meeting
THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® (denosumab) at this year's Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Denver from Sept. 8-11, 2017.
"The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific understanding and care for the millions of people living with osteoporosis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Although those who suffer fractures often experience pain1 and face potential loss of their independence2, only about one-fifth of patients with a fracture are treated for the underlying disease3. We are pleased to share our latest research with the bone community as we work together to help solve the public health crisis in osteoporosis4."
"The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific understanding and care for the millions of people living with osteoporosis," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Although those who suffer fractures often experience pain1 and face potential loss of their independence2, only about one-fifth of patients with a fracture are treated for the underlying disease3. We are pleased to share our latest research with the bone community as we work together to help solve the public health crisis in osteoporosis4."